Tricida (TCDA) Tops Q2 EPS by 17c

Tricida (NASDAQ: TCDA) reported Q2 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

As of June 30, 2021, cash, cash equivalents and investments were $175.8 million.

GUIDANCE:

Tricida believes it has financial resources to fund its planned operations into late 2022. Based on the current rate of primary endpoint events in the VALOR-CKD trial, the 250-event interim analysis for early stopping for efficacy of the trial is expected to occur within the time frame of our existing capital. If we are compelled to stop the trial early for administrative reasons, that event could occur prior to the planned 250-event interim analysis.

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy